Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 24, 2008
JNCI Journal of the National Cancer Institute 2008 100(13):907; doi:10.1093/jnci/djn256
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/13/907-a    most recent
djn256v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

MEMO TO THE MEDIA

Activation of LYN Kinase Is Associated with Imatinib-Resistance in CML Patients

The first 10% of the full text of this article appears below.

Activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML), researchers report in the June 24 online issue of the Journal of the National Cancer Institute.

Imatinib is the standard therapy for newly diagnosed CML patients. However, some patients develop resistance to the drug over time. In some patients, resistance develops . . . [Full Text of this Article]

Contact:

Citation:

Note to Reporters:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
Ji Wu, Feng Meng, Ling-Yuan Kong, Zhenghong Peng, Yunming Ying, William G. Bornmann, Bryant G. Darnay, Betty Lamothe, Hanshi Sun, Moshe Talpaz, and Nicholas J. Donato
J Natl Cancer Inst 2008 100: 926-939. [Abstract] [Full Text] [PDF]

Persistent LYN Signaling in Imatinib-Resistant, BCR-ABL–Independent Chronic Myelogenous Leukemia
Thomas O'Hare, Christopher A. Eide, and Michael W. Deininger
J Natl Cancer Inst 2008 100: 908-909. [Extract] [Full Text] [PDF]